跳至主要内容
临床试验/NL-OMON43064
NL-OMON43064已完成不适用

A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN HEALTHY VOLUNTEERS TO DETERMINE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ESCALATING MULTIPLE DOSES OF MMI-0100 OR PLACEBO ADMINISTERED BY PULMONARY DELIVERY - MMI-0100 MAD study

Moerae Matrix, Inc0 个研究点目标入组 32 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
32

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • healthy male or female
  • Age: between 18 and 55 years of age, inclusive
  • BMI: between 19.0 and 30.0 kilograms/meter2
  • Body weight: between 50.0 and 100.0 kg, inclusive

排除标准

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within
  • 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of
  • donating more than 1.5 liters of blood in the 10 months prior the start of this study.

研究者

相似试验

A PHASE 1, DOUBLE-BLIND, RANDOMIZED,... | 临床试验